EDIT/USD – 30-Min Long Trade Setup !📌 🚀
🔹 Asset: EDIT (Editas Medicine, Inc.)
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Bullish Breakout Trade
📌 Trade Plan (Long Position)
✅ Entry Zone: Above $1.85 (Breakout Confirmation)
✅ Stop-Loss (SL): Below $1.67 (Support Breakdown)
🎯 Take Profit Targets:
📌 TP1: $2.07 (First Resistance Level)
📌 TP2
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.7846 EUR
−229.03 M EUR
31.21 M EUR
82.93 M
About Editas Medicine, Inc.
Sector
Industry
CEO
Gilmore O’Neill
Website
Headquarters
Cambridge
Founded
2013
FIGI
BBG00C5XQ159
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
EDIT/USD – 30-Min Long Trade Setup !📊 🚀
🔹 Asset: EDIT/USD
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Rising Wedge Breakout
🚀 Trade Plan (Long Position):
✅ Entry Zone: Above 1.75 USD (Breakout Confirmation)
✅ Stop-Loss (SL): Below 1.60 USD (Breakout Invalidated)
🎯 Take Profit Targets:
📌 TP1: 1.92 USD (First Resistance Level)
📌 TP2: 2.10
EDIT BULLISHEditas Medicine (NASDAQ: EDIT) is focused on developing CRISPR-based gene-editing technologies and has a solid pipeline for treating various genetic diseases, cancers, and autoimmune conditions. They've partnered with major players like Bristol Myers Squibb and Vertex Pharmaceuticals, boosting their
EDIT buildupHello traders, usually I analyze companies with a higher market cap than EDIT due to liquidity and a clear path. however, this time its different (hah). Ok now, lets get to the good stuff. EDIT's ruby trial went well and their participants have showed promising signs that their treatment is working.
EDITAS bottoming in process, turnaround soon, target min ~22 USDEDITAS could be in the bottoming process, I am watching it for a few years now.
We have a falling broadening wedge, on which we had a breakout already. This is part of a bigger falling wedge (blue).
It is techincally possible, we had put in the lows at 6.35 as a wave 5 (as an ending diagonal), wh
Edit Another support hold here 13.13. No price below these levels here personally I love this company and think they are going to do big things. This is a long term trade and great entry price. Of course you still have to manage risk which would mean closing weekly body below 13.13 could signal downside
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Editas Medicine Inc. stocks are traded under the ticker 8EM.
We've gathered analysts' opinions on Editas Medicine Inc. future price: according to them, 8EM price has a max estimate of 7.04 EUR and a min estimate of 0.88 EUR. Watch 8EM chart and read a more detailed Editas Medicine Inc. stock forecast: see what analysts think of Editas Medicine Inc. and suggest that you do with its stocks.
Yes, you can track Editas Medicine Inc. financials in yearly and quarterly reports right on TradingView.
Editas Medicine Inc. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
8EM earnings for the last quarter are −0.53 EUR per share, whereas the estimation was −0.36 EUR resulting in a −45.75% surprise. The estimated earnings for the next quarter are −0.51 EUR per share. See more details about Editas Medicine Inc. earnings.
Editas Medicine Inc. revenue for the last quarter amounts to 29.56 M EUR, despite the estimated figure of 28.74 M EUR. In the next quarter, revenue is expected to reach 644.04 K EUR.
8EM net income for the last quarter is −43.85 M EUR, while the quarter before that showed −55.81 M EUR of net income which accounts for 21.43% change. Track more Editas Medicine Inc. financial stats to get the full picture.
No, 8EM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 29, 2025, the company has 246 employees. See our rating of the largest employees — is Editas Medicine Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Editas Medicine Inc. EBITDA is −225.18 M EUR, and current EBITDA margin is −721.39%. See more stats in Editas Medicine Inc. financial statements.
Like other stocks, 8EM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Editas Medicine Inc. stock right from TradingView charts — choose your broker and connect to your account.